

Anthropometric predictors of relapse from severe acute malnutrition: towards evidence-based discharge criteria







Benjamin Guesdon, PhD¹, Manisha Katwal², Amod Kumar Poudel, PhD³, Tulsi Ram Bhandari,PhD⁴, Emilie Counil, PhD⁵, Sujay Nepali²

¹Action Against Hunger | Action Contre la Faim (ACF) - France, 14-16 Boulevard Douaumont, 75854 Paris, France. ²Action Against Hunger | Action Contre la Faim (ACF) - Nepal, Kathmandu, Nepal. ³Central Department of Public Health, Institute of Medicine (IOM), Tribhuvan University (TU), Maharajgunj, Nepal. ⁴Department of Public Health, School of Health and Allied Sciences, Pokhara University (PoU), Pokhara, Nepal. ⁵Institut national d'études démographiques (INED), F-93322 Aubervilliers, France.

Background


There is a dearth of evidence on what should be the optimal criteria for discharging children from severe acute malnutrition (SAM) treatment. Posttreatment outcomes follow-up in children discharged as cured with variable levels of anthropometric deficits is instrumental to fill current evidence gaps about the adequacy of current international recommendation and the extent to which different types of anthropometric deficits at discharge, including Weight-for-Height (WHZ) deficits, influence the risk of relapse. In Nepal, SAM children are managed and treated as per the national guideline on Integrated Management of Acute Malnutrition (IMAM). According to this guidance, all internationally agreedupon case definitions of SAM (low Mid Upper Arm Circumference (MUAC) or low WHZ or nutritional Oedema) are eligible for treatment, yet discharge criteria are less stringent than WHO standards: they mainly consist in the observation of a MUAC > 115 mm after a minimum treatment duration of 6 weeks. Many children may thus be discharged from SAM treatment while still presenting anthropometric deficits. The resulting risks have never been assessed. In particular it is unknown if (or to what extent) this may predispose to relapse or if instead, the child recovery process would continue after treatment cessation.

Aim

- describe the relapse rates among the severely acutely malnourished children discharged as cured from the IMAM programme.
- quantify the strength of the association between failure to reach WHOrecommended discharge criteria and risk of relapse, and
- identify the respective contributions of the different types of anthropometric deficits

Methodology

A prospective observational study of a cohort of SAM children discharged as cured from the IMAM programme was conducted. SAM children aged 6 to 59 months at their admission to treatment, and who were discharged as cured as per national recommendations from the 14 health facilities implementing outpatient treatment in the district were the target population. The recruitment period started in July 2019, for a period of one year. The IMAM programme registers of the health facilities were screened each week in order to identify children newly discharged as cured as per national protocol: a minimum length of 6 weeks AND MUAC >115 mm AND no Oedema for two consecutive visits AND weight gain for last two consecutive visits AND clinically well and alert. Families were then promptly reached using either direct phone contact or indirect contact through the community health workers in charge of the area. Children eligible for the study were all new children discharged as cured (1) for whom a home visit could be planned for a formal recruitment interview with the caretaker at a date close to two weeks after discharge; and (2) for whom the caretaker did not report any plan to leave the district in the next 6 months.



Patient's flow chart

Result

The results suggest that children who are apparently successfully treated for SAM as per current national guidance in Nepal have a high risk of relapse as SAM within 6 months after end of treatment. This risk of relapse appears to be primarily explained by the fact that the current guidance allows discharging children as cured before they reach the WHO-recommended discharge criteria. Among the anthropometric deficits at discharge contributing to the risk of relapse as SAM, it is shown that WHZ deficits plays a unique role.

Table: Cox proportional-hazards analysis of the association between anthropometric deficits at discharge and risk of relapse

Hazard Ratio P Hazard Ratio P Hazard Ratio	Exposure variables		Proportion of relapse (%)	Univariate models		Multivariate models	
variables WHZ at discharge WHZ<-2 WHZ>=-2 45.3 (24/53) (24/53) (20/72) 3.2 Ref. 0.003 Ref. 2.8 Ref. 0.01 MUAC at discharge MUAC 41.7 (15/36) MUAC>=125mm 1.5 August 0.26 Ref. 1.4 August 0.32 Ref. HAZ at discharge HAZ<-2 August					p		p
discharge WHZ>=-2 20.0 (11/55) Ref. Ref. Ref. MUAC at discharge MUAC>=125mm 41.7 (15/36) 1.5 0.26 1.4 0.32 HAZ at discharge HAZ<=2 32.8 (20/72) Ref. Ref. NA NA Juration of treatment 41.0 weeks 22.8 (13/57) 0.5 0.051 0.7 0.27 Juration of treatment 43.1 (22/51) Ref. Ref. NA NA Juration of treatment 424 months 32.8 (21/64) 0.9 0.74 NA NA Juration of treatment 31.8 (14/44) Ref. Ref. Ref. NA NA Sex Male 40.0 (20/50) 1.7 0.14 1.6 0.23 Models with continuous exposure variables NA 0.19 <0.001 0.2 0.001 MUAC at discharge NA 0.81 0.24 NA NA HAZ at discharge in mm NA 0.81 0.24 NA NA Duration of		n binary exposure					
discharge MUAC>=125mm 27.8 (20/72) Ref. Ref. HAZ at discharge HAZ>=-2 32.8 (20/61) 1.1 0.75 NA NA Duration of treatment <10 weeks 22.8 (13/57) 0.5 0.051 0.7 0.27 Age at discharge <24 months 32.8 (21/64) 0.9 0.74 NA NA Sex Male 40.0 (20/50) 1.7 0.14 1.6 0.23 Female 25.9 (15/58) Ref. Ref. Ref. Ref. MOdels with continuous exposure variables WHZ at discharge NA 0.19 <0.001 0.2 0.001 MUAC at discharge NA 0.94 0.046 1.0 0.10 HAZ at discharge NA 0.81 0.24 NA NA Duration of treatment in days NA 1.0 0.10 1.0 0.86 Age at discharge in months NA 1.0 0.94 NA NA Sex Male 40.0 (20/50)			,		0.003		0.01
discharge HAZ>=-2 31.9 (15/47) Ref. Duration of treatment <10 weeks 22.8 (13/57) 0.5 0.051 0.7 0.27 Age at treatment >=10 weeks 43.1 (22/51) Ref Ref Ref. Age at discharge <24 months 32.8 (21/64) 0.9 0.74 NA NA Age at discharge Male 40.0 (20/50) 1.7 0.14 1.6 0.23 Female 25.9 (15/58) Ref. Ref. Ref. Models with continuous exposure variables WHZ at discharge NA 0.19 <0.001 0.2 0.001 MUAC at discharge in mm NA 0.94 0.046 1.0 0.10 HAZ at discharge NA 0.81 0.24 NA NA Duration of treatment in days NA 1.0 0.10 1.0 0.86 Age at discharge in months NA 1.0 0.94 NA NA Age at discharge in months NA 1.0 0.14 1.7 <th></th> <th></th> <th>,</th> <th></th> <th>0.26</th> <th></th> <th>0.32</th>			,		0.26		0.32
Age at discharge Value of the continuous exposure variables NA			,		0.75	NA	NA
discharge >=24 months 31.8 (14/44) Ref. Sex Male Female 40.0 (20/50) 1.7 Pemale 1.7 Pemale 0.14 Pemale 1.6 Ref. Models with continuous exposure variables WHZ at discharge NA 0.19 Pemale <0.001 Pemale			,		0.051		0.27
Female 25.9 (15/58) Ref. Ref. Ref.			,		0.74	NA	NA
exposure variables WHZ at discharge NA 0.19 <0.001	Sex		,		0.14		0.23
MUAC at discharge in mm NA 0.94 0.046 1.0 0.10 HAZ at discharge NA 0.81 0.24 NA NA Duration of treatment in days NA 1.0 0.10 1.0 0.86 Age at discharge in months NA 1.0 0.94 NA NA Sex Male 40.0 (20/50) 1.7 0.14 1.7 0.19							
HAZ at discharge NA 0.81 0.24 NA NA Duration of treatment in days NA 1.0 0.10 1.0 0.86 Age at discharge in months NA 1.0 0.94 NA NA Sex Male 40.0 (20/50) 1.7 0.14 1.7 0.19	WHZ at discharge		NA	0.19	< 0.001	0.2	0.001
Duration of treatment in days NA 1.0 0.10 1.0 0.86 Age at discharge in months NA 1.0 0.94 NA NA Sex Male 40.0 (20/50) 1.7 0.14 1.7 0.19	MUAC at discharge in mm		NA	0.94	0.046	1.0	0.10
Age at discharge in months NA 1.0 0.94 NA NA Sex Male 40.0 (20/50) 1.7 0.14 1.7 0.19	HAZ at discharge		NA	0.81	0.24	NA	NA
Sex Male 40.0 (20/50) 1.7 0.14 1.7 0.19	Duration of treatment in days		NA	1.0	0.10	1.0	0.86
	Age at discharge in months		NA	1.0	0.94	NA	NA
	Sex		,		0.14	1.7	0.19

WHZ: weight-for-height Z-score; MUAC: Mid-upper arm circumference; HAZ: height-for-age Z-score

Table: Incidence rates of relapse as SAM (by 100 child-months)

period	Over the 6 months follow-up		Over the first 3 months		Over the last 3 months	
	Incidence Rate	95% CI	Incidence Rate	95% CI	Incidence Rate	95% CI
Relapse as SAM	7.2	5.1-10.1	10.9	7.5-15.9	2.5	1.0-6.0

parameter at discharge significantly associated with relapse as SAM was WHZ.

The only anthropometric

33.3% of the discharged children relapsed as SAM, 77.1% of which occurred in the first three months after discharge

Failure to reach WHO recommended criteria at discharge greatly increased the risk (42.6%) of relapse as SAM within 6 months after treatment cessation

Still being MAM at discharge multiplied the risk of relapse as SAM by almost 3.

Conclusion

The results suggest that priority should be given to ensure that the children enrolled in SAM management programmes reach a high level of WHZ at discharge, at least above or equal to the WHO-recommended cut-off, and that the correction of MUAC deficits should not be considered as a sufficient discharge criterion. Besides, the validity of using a single MUAC cut-off such as 125 mm as a criterion to end treatment in all age groups should be further ascertained. Robust investigations of relapse providing a complete assessment of nutritional status at discharge, and using all possible case definitions of SAM to define relapse as SAM, should be performed in a variety of contexts, including in the context of MUAC-only protocols. This is required to assess the current burden of relapse across programmes and to build the evidence base for setting discharge criteria that secure sustained recovery and healthy growth in most of the children. In the meanwhile, it is believed that current international and national guidance encouraging the practice of leaving SAM children's WHZ status unassessed, at admission to and discharge from treatment, and the use of restricted MUAC-only definitions of relapse, should be promptly revised in the light of the research findings.

Acknowledgements

Action Contre la Faim (ACF) research foundation for financial support; all municipalities of Nawalparasi West district, District coordination Committee of Nawalparasi West and Nepal Health Research Council for providing their approval for the research; Health Office, Nawalparasi West district and Ministry of Health and Population for their multivariate analysis support.